Cr Pharmaceutical
Cr Pharmaceutical, officially known as China Resources Pharmaceutical Group Limited, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Established in 1992, the company has grown significantly, with a strong presence in major operational regions across China and beyond. Specialising in the research, development, manufacturing, and distribution of a wide range of pharmaceutical products, Cr Pharmaceutical is renowned for its commitment to quality and innovation. Its core offerings include prescription medications, over-the-counter drugs, and healthcare products, all designed to meet the diverse needs of patients and healthcare providers. With a robust market position, Cr Pharmaceutical has achieved notable milestones, including strategic partnerships and expansions that enhance its competitive edge. The company continues to focus on advancing healthcare solutions, solidifying its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Cr Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cr Pharmaceutical's score of 31 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cr Pharmaceutical's reported carbon emissions
In 2023, Cr Pharmaceutical reported total carbon emissions of approximately 725,648,620 kg CO2e, with Scope 1 emissions at about 170,536,140 kg CO2e and Scope 2 emissions at approximately 555,112,180 kg CO2e. The company has disclosed emissions data for Scopes 1 and 2, but no data for Scope 3 emissions is available for this year. In 2022, the total emissions were approximately 774,980,600 kg CO2e, with Scope 1 at about 160,986,950 kg CO2e and Scope 2 at approximately 613,993,650 kg CO2e. The trend shows a decrease in total emissions from 2022 to 2023. Cr Pharmaceutical has not set specific reduction targets or initiatives as per the latest data, indicating a lack of formal commitments to reduce emissions through frameworks such as the Science Based Targets initiative (SBTi). The company continues to monitor and report its emissions, reflecting an awareness of its environmental impact, but further commitments or strategies for significant reductions have not been disclosed.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 00,000 | 00,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 0,000,000 | 0,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cr Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
